person
Guillaume B.
- Country
- France
- Department
- gastroenterology
Research Overview
assignment
20
Clinical Trials ·
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
245
Sites with multiple studies
Has run more than one trial at 245 of 454 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating complex manifestations of Crohn's disease and ulcerative colitis, with particular emphasis on developing innovative therapeutic approaches.
- Perianal Crohn's Disease Treatment
- Moderate to Severe Disease States
- Post-operative Recurrence Prevention
Advanced Therapeutic Interventions
Focus areas include the evaluation of novel biological therapies and targeted treatments for inflammatory bowel conditions, including:
- Combination Therapy Approaches
- Therapeutic Drug Monitoring
- Treatment Optimization Strategies
Innovative Treatment Modalities
Expertise in investigating emerging therapeutic options including fecal microbiota transplantation and maintenance therapy optimization for:
- Pouchitis Management
- Disease Remission Maintenance
- Treatment Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.